Deep Brain Stimulation Devices Market to Reach US$2.24 Billion by 2035, Driven by Rising Neurological Disorders

The global Deep Brain Stimulation Devices Market reached USD 944.44 million in 2025 and is expected to reach USD 2,235.84 million by 2035, growing at a CAGR of 9.0% during the forecast period 2026-2035. The market is gaining momentum as the prevalence of Parkinson's disease, essential tremor, dystonia, and other neurological disorders increases demand for advanced neuromodulation therapies. Continuous improvements in stimulation technologies, implantable pulse generators, electrode designs, and programming capabilities are further supporting the adoption of deep brain stimulation devices.

The competitive opportunity is increasingly focused on minimally invasive procedures, rechargeable systems, adaptive stimulation, precision targeting, and personalized neuromodulation. Manufacturers are investing in advanced DBS technologies designed to improve stimulation accuracy, battery performance, patient comfort, and long-term treatment outcomes. The market is therefore shifting toward next-generation neurostimulation systems, closed-loop and adaptive DBS, improved imaging-guided implantation, rechargeable devices, and patient-specific treatment approaches, supporting sustained growth in the global Deep Brain Stimulation Devices Market through 2035.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/deep-brain-stimulation-devices-market?sai-v

Recent Developments
August 2026: North America continued leading the deep brain stimulation devices market, supported by established neuromodulation infrastructure and continued innovation in Parkinson's disease treatment. Medtronic also received FDA approval for a manufacturing-process update to its Activa/Percept PC BrainSense DBS system.

July 2026: Asia-Pacific continued expanding DBS adoption as neurological disease burden, specialist-care capacity, and access to advanced neuromodulation therapies increased across China, Japan, South Korea, and India. The region is also seeing greater research activity in adaptive and personalized DBS.

June 2026: Europe continued advancing next-generation DBS technologies, with research increasingly focused on adaptive stimulation, closed-loop systems, AI-assisted targeting, and personalized programming to improve therapeutic outcomes and reduce stimulation-related side effects.

May 2026: Abbott continued strengthening its DBS portfolio, with an FDA-approved supplement in 2026 covering manufacturing-process changes for its implantable pulse generator used in Parkinsonian tremor treatment.

April 2026: The global DBS industry increasingly focused on AI-enabled targeting, adaptive stimulation, real-time neural sensing, and personalized programming. A 2026 systematic review covering 239 studies found growing AI applications across targeting, programming, outcome prediction, and adaptive therapy, although most technologies remain in early-to-intermediate stages of clinical translation.

Key Players

Medtronic plc | Boston Scientific Corporation | Abbott Laboratories | Aleva Neurotherapeutics | NeuroPace, Inc. | SceneRay Co., Ltd. | PINS Medical | Renishaw plc. | BrainsWay Ltd. | inomed Medizintechnik GmbH | Others

Key Highlights
Medtronic plc - Holds a 41.5% share, supported by its extensive DBS product portfolio, strong global presence, established clinical ecosystem, and continued investment in advanced neuromodulation technologies.

Boston Scientific Corporation - Holds a 12.2% share, driven by its advanced neurostimulation portfolio, directional stimulation technologies, clinical research capabilities, and expanding DBS applications.

Abbott Laboratories - Holds a 22.3% share, strengthened by its Infinity DBS system, directional lead technology, programming capabilities, and broad neuromodulation portfolio.

Aleva Neurotherapeutics - Holds a 0.5% share, supported by its specialized DBS technologies and focus on precision neuromodulation solutions.

NeuroPace, Inc. - Holds a 5.0% share, driven by its expertise in responsive neurostimulation and development of advanced implantable technologies for neurological disorders.

SceneRay Co., Ltd. - Holds a 2.0% share, supported by its DBS systems, growing presence in China, and focus on cost-effective neuromodulation technologies.

PINS Medical - Holds a 2.0% share, strengthened by its DBS devices, local manufacturing capabilities, and expanding position in the Chinese neuromodulation market.

Renishaw plc. - Holds a 0.5% share, supported by its precision engineering expertise and development of stereotactic neurosurgical and DBS-related technologies.

BrainsWay Ltd. - Holds a 1.0% share, supported by its non-invasive deep brain stimulation technologies and focus on advanced neuromodulation applications.

inomed Medizintechnik GmbH - Holds a 0.5% share, driven by its neurosurgical technologies, intraoperative monitoring systems, and solutions supporting precision neurological procedures.

Others - Hold a combined 12.5% share, comprising LivaNova PLC, Functional Neuromodulation Ltd., Newronika S.p.A., NeuroSigma, Synapse Biomedical, NeuroOne Medical Technologies, and other emerging neuromodulation companies.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=deep-brain-stimulation-devices-market?sai-v

Market Drivers
- Rising prevalence of neurological disorders such as Parkinson's disease, essential tremor, dystonia, and other movement disorders, increasing demand for advanced neuromodulation therapies.

- Growing adoption of deep brain stimulation (DBS) as an established treatment option for patients with medication-refractory movement disorders.

- Increasing geriatric population and growing incidence of age-associated neurological disorders, expanding the potential patient pool for DBS procedures.

- Rising advancements in implantable pulse generators, electrodes, programming systems, and rechargeable DBS technologies, improving treatment flexibility and patient convenience.

- Growing demand for minimally invasive and personalized neurosurgical treatment options that can provide long-term symptom management.

- Increasing investments in neurological research, neuromodulation technologies, and clinical studies aimed at expanding DBS applications.

- Growing adoption of image-guided surgery, robotics, artificial intelligence, and advanced brain-mapping technologies to improve DBS implantation accuracy.

Industry Developments
- Development of next-generation DBS systems featuring rechargeable batteries, directional leads, sensing capabilities, and more precise stimulation control.

- Increasing integration of artificial intelligence, adaptive stimulation, brain sensing, and data analytics to enable more personalized DBS therapy.

- Strategic collaborations between medical device companies, neurosurgical centers, research institutions, and technology providers to advance neuromodulation solutions.

- Expansion of clinical research evaluating DBS for additional neurological and neuropsychiatric conditions beyond traditional movement-disorder applications.

- Increasing adoption of robotic and image-guided DBS implantation systems designed to improve surgical precision and reduce procedural variability.

- Growing development of remote programming, connected DBS platforms, and digital monitoring technologies to support long-term patient management.

Regional Insights
North America - 41% share: "Driven by advanced neurosurgical infrastructure, high prevalence of neurological disorders, strong adoption of neuromodulation technologies, and significant investment in neurological research."

Europe - 30% share: "Supported by established neurological care networks, advanced neurosurgical capabilities, growing adoption of DBS therapy, and increasing research into innovative neuromodulation technologies."

Asia Pacific - 23% share: "Fueled by a growing aging population, rising neurological disease burden, improving healthcare infrastructure, increasing awareness of DBS, and expanding access to advanced neurosurgical treatments."

Latin America - 4% share: "Supported by improving neurological care infrastructure, increasing diagnosis of movement disorders, and growing access to specialized neurosurgical and neuromodulation services."

Middle East & Africa - 2% share: "Driven by improving healthcare infrastructure, increasing awareness of advanced neurological treatments, expanding specialized neurosurgical centers, and growing adoption of DBS technologies."

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/deep-brain-stimulation-devices-market?sai-v

Key Segments
➥ By Product Type

Implantable Pulse Generators: Represents the dominant segment, driven by the essential role of pulse generators in delivering controlled electrical stimulation and increasing adoption of DBS for neurological disorders.

Electrodes: Represents a significant segment, supported by their critical role in targeting specific brain regions and delivering precise electrical stimulation during DBS procedures.

Extension Leads: Represents an important segment, fueled by their function in connecting implanted electrodes with pulse generators and the continued need for reliable stimulation pathways.

Others: Represents a growing segment, supported by continued development of DBS accessories, programming systems, chargers, and other components that improve treatment management.

➥ By Battery Type

Rechargeable: Represents the dominant and rapidly growing segment, driven by longer device lifespan, reduced need for replacement surgeries, improved patient convenience, and increasing adoption of advanced DBS systems.

Non-Rechargeable: Represents a significant segment, supported by established clinical use, simpler maintenance requirements, and continued demand for DBS devices using conventional battery technology.

➥ By Stimulation Type

Single-Channel Stimulation: Represents a significant segment, driven by its suitability for selected neurological conditions and established use in targeted brain stimulation procedures.

Dual-Channel Stimulation: Represents the dominant segment, supported by the ability to deliver stimulation to multiple targeted areas and increasing adoption for complex neurological disorders requiring bilateral brain stimulation.

➥ By Application

Parkinson's Disease: Represents the dominant segment, driven by the established clinical use of DBS for managing motor symptoms in patients with advanced Parkinson's disease and increasing prevalence of the condition.

Essential Tremor: Represents a significant segment, supported by the effectiveness of DBS in reducing severe tremors and increasing adoption among patients who do not achieve adequate control with medication.

Dystonia: Represents an important segment, fueled by growing recognition of DBS as a treatment option for selected patients with medically refractory dystonia.

Epilepsy: Represents a growing segment, supported by increasing research and adoption of neuromodulation approaches for patients with drug-resistant epilepsy.

Obsessive-Compulsive Disorder (OCD): Represents an emerging segment, driven by continued clinical research and specialized use of DBS for severe treatment-resistant OCD.

Others: Represents a growing segment, supported by expanding research into DBS applications for additional neurological and neuropsychiatric disorders.

➥ By End-User

Hospitals: Represents the dominant segment, driven by the availability of advanced neurosurgical infrastructure, specialized neurologists and neurosurgeons, and comprehensive facilities required for DBS implantation and follow-up care.

Specialty Clinics: Represents a significant and growing segment, supported by increasing demand for specialized neurological care, DBS programming, patient monitoring, and long-term therapy management.

Ambulatory Surgical Centers: Represents a growing segment, fueled by the increasing shift toward specialized outpatient procedures, advances in minimally invasive neurosurgical techniques, and demand for efficient treatment settings.

Others: Represents an expanding segment, supported by adoption across research institutions, neurological centers, and other specialized healthcare facilities involved in DBS treatment and clinical research.

Explore Report Here: https://www.datamintelligence.com/research-report/deep-brain-stimulation-devices-market

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.